Exactis Innovation

Pan-Canadian registry of close to 10,000 patients across 16 cancer centres. Canada's largest longitudinal dataset of clinical and biomarker data.

[Exactis Innovation @ExactisI]

Ever wondered how federal budgets are crafted and how #healthcare is prioritized in Canada? We’re thrilled to welcome @tylermeredith, past Senior Economic Advisor for @CanadianPM and @DeputyPM_Canada who helped deliver 6 federal budgets on #WhatsWithRWE! https://t.co/YKWQ4oIEV6

[Exactis Innovation @ExactisI]

Aaron Leibtag from @Pentavere (acquired by @Healwell_AI), a leading Canadian AI health technology company, joins us on #WhatsWithRWE to share the challenges he and his team faced in building their company, and how #AI can revolutionize #healthcare.
https://t.co/dml6j8UXc5

[Exactis Innovation @ExactisI]

Our latest episode of #WhatsWithRWE is now live! 🎉 In this episode, we’re thrilled to welcome Tim Errington, Senior Director of Research at @OSFramework! Join Tim and Lester as they dive into the ins and outs of replicating scientific studies. #research
https://t.co/UssZb9uOg1

[Exactis Innovation @ExactisI]

✨New episode of #WhatsWithRWE! We're honored to be joined by @clopezcorrea, CSO of @genomecanada. She shares her path into the fascinating world of genomics, and how this insight guided her cancer treatment when she was diagnosed with breast cancer. https://t.co/q5l93H4Whx

[Exactis Innovation @ExactisI]

This #DNADay, we're celebrating @clopezcorrea, CSO of @GenomeCanada, cancer survivor, and most recent guest on #WhatsWithRWE! As a #genomics scientist, she had a unique insight into the world of genomic profiling and how it could help her fight #cancer. https://t.co/wnjFIXo3JH

[Exactis Innovation @ExactisI]

🎙️Chere from @ArdeaOutcomes explains how goal attainment scaling gathers data that reflects what truly matters to patients, and how this approach unveils a more comprehensive depiction of a drug’s effects during #clinicaltrials. #clinicalresearch
https://t.co/5tWhhRTNFt

[Exactis Innovation @ExactisI]

🚨 New release of #WhatsWithRWE! We spoke with Chere Chapman, CEO of @ArdeaOutcomes, a Canadian CRO focusing on goal attainment scaling (GAS) in #clinicaltrials. Watch the short video below (5 min) as Chere dives into the genesis of the organization.
https://t.co/l3XbhPySBZ

[Exactis Innovation @ExactisI]

#WhatswithRWE🎙️With #pharmacare closer to reality in Canada, market access professionals Sang Mi Lee and Brian O'Rourke shed light on Canada's #drug reimbursement system and how it might evolve with the recent creation of the #CanadianDrugAgency.
https://t.co/Es0eFacIVo

[Exactis Innovation @ExactisI]

Time to unveil the results of last week's poll! 📊
How long does it take for a new #drug in Canada to go from @GovCanHealth authorization to reimbursement?

The answer is on average 632 days!

In a comparison of 20 #OECD countries, Canada ranked 19th. #LastMileforMedicines

[CDA-AMC @CDA_AMC]

New from our Post-Market Drug Evaluation Program and CoLab Network — a post-market study on the real-world safety #niraparib for #ovariancancer /1

📘 https://t.co/bHFE92sXd6

#cdnHealth #HTA #RealWorldEvidence #RWE

[Exactis Innovation @ExactisI]

Poll!📊How many days on average do you think it takes for a new #drug in Canada to go from @GovCanHealth authorization to reimbursement by provinces? Based on data from @innovativemeds and @IQVIA_global @cancersociety #cancer #cancerresearch

[Exactis Innovation @ExactisI]

Our colleague @G4DNA is representing us at the Canadian Lung Cancer Conference in Vancouver today! It's a perfect opportunity to share a clip of our conversation with Dr Natasha Leighl, an expert in #lungcancer and #liquidbiopsies. #WWRWE #CLCC
https://t.co/ppToRyA1La

[Exactis Innovation @ExactisI]

The approval of new #cancer therapies usually relies on #clinicaltrials. But how do we know how these therapies affect patients in the real world? Dr Natasha Leighl from @UHN highlights how #RWE studies can fill this gap by collecting real-world data #RWD
https://t.co/MdwtYy3j6q

[Exactis Innovation @ExactisI]

🎙 The new season of #WhatsWithRWE is here! We spoke with Dr. Natasha Leighl, medical oncologist at @pmcancercentre at @UHN, professor at @UofT, and lead researcher on @GuardantHealth's liquid biopsy for targeted treatment selection study. #CancerResearch
https://t.co/YimsrMcCPD

[Exactis Innovation @ExactisI]

We're proud to announce the #publication of our #research featured in the @IJMS_MDPI. This paper represents the extensive efforts of our team to understand the safety and efficacy of regorafenib as a second-line treatment for metastatic #colorectalcancer.
https://t.co/Vpc2j8qG0l

[Exactis Innovation @ExactisI]

We were thrilled to present our PMT Databank with esteemed hematologist-oncologists at the Montreal Jewish General Hospital last month. We are excited to announce that we are working to add hematological cancer patient data to our already robust databank. #RWE #RWD

[Exactis Innovation @ExactisI]

We are excited to collaborate with @SOPHiAGENETICS on accelerating data-driven discoveries by unlocking diverse insights from #RealWorldData from around the world. Read more at the link below!
#collaboration #RWE #RWD #precisionmedicine
https://t.co/SB1SSXk11z

[Exactis Innovation @ExactisI]

Our podcast #WhatswithRWE? has surpassed our expectations by producing six episodes this year. We focus on the transformative potential of #realworlddata in Canadian #cancercare. Watch below as @ktrakas and @G4DNA reflect on their favorite moments.
#RWE
https://t.co/jWpIg9KqR5

[Exactis Innovation @ExactisI]

#HappyHolidays from all of us at Exactis Innovation!

[Exactis Innovation @ExactisI]

When faced with a cancer diagnosis, many patients turn to "Dr. Google." @BreastCancerCDN has developed a better option that aims to deliver highly pertinent and comprehensive results for those seeking answers following a breast cancer diagnosis.
https://t.co/oTDv6f6LMf